Sign In
Buy AZN
$181.02
+4.59 (+2.60%)
At Close: Jun 23, 2026
AZN Q4 Earnings Lag, Sales Beat, Stock Up on China Probe Update
12:17pm, Thursday, 06'th Feb 2025
AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business impact of the Chinese investigations remains minor.
AstraZeneca PLC (AZN) Q4 2024 Earnings Call Transcript
12:16pm, Thursday, 06'th Feb 2025
AstraZeneca PLC (NASDAQ:AZN ) Q4 2024 Earnings Conference Call February 6, 2025 6:00 AM ET Company Participants Pascal Soriot – Executive Director and Chief Executive Officer Iskra Reic – Executiv
AstraZeneca PLC Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - AZN
11:30am, Thursday, 06'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities law
AstraZeneca PLC Is Being Sued For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm
11:00am, Thursday, 06'th Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 6, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZe
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term
10:51am, Thursday, 06'th Feb 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Astrazeneca (AZN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
10:36am, Thursday, 06'th Feb 2025
While the top- and bottom-line numbers for Astrazeneca (AZN) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics com
AstraZeneca Q4 Earnings: Revenue And EPS Beat On Higher Cancer And Respiratory Drug Sales, Faces $4.5 Million Potential Fine In China
08:40am, Thursday, 06'th Feb 2025
On Thursday, AstraZeneca Plc AZN reported fourth-quarter sales of $14.89 billion, up 18% year over year (+19% at constant currency), beating the consensus of $14.29 billion.
Shareholders that Lost Money on AstraZeneca PLC (AZN) Should Contact Levi & Korsinsky About Pending Class Action - AZN
07:30am, Thursday, 06'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities law
NEW YORK CITY, NY / ACCESS Newswire / February 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Ast
The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZN
05:45am, Thursday, 06'th Feb 2025
NEW YORK , Feb. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN). Shareholders who purchased shares of AZN during the class peri
AstraZeneca: China exposure manageable, says investment bank
05:15am, Thursday, 06'th Feb 2025
AstraZeneca PLC (LSE:AZN) could face a fine of up to £4.5 million as the Chinese authorities investigate allegedly illegal imports of cancer drugs Imfinzi and Imjudo. The Shenzhen City Customs suspe
AstraZeneca receives £6bn boost as earnings beat forecasts
03:28am, Thursday, 06'th Feb 2025
AstraZeneca PLC (LSE:AZN) shares climbed 3.5% in early trading, adding £6 billion to its market value, after reporting strong annual profits driven by its cancer, lung, and immunology treatments. Re
AstraZeneca 2025 sales outlook tops expectations
02:10am, Thursday, 06'th Feb 2025
AstraZeneca forecast its 2025 sales above analysts' expectations on Thursday, after the drugmaker's fourth-quarter revenue beat estimates, driven by robust demand, especially for its medicines for can
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of AstraZeneca PLC(AZN) Shareholders
04:45pm, Wednesday, 05'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities law
AZN Investors Have Opportunity to Lead AstraZeneca PLC Securities Fraud Lawsuit Filed by The Rosen Law Firm
04:29pm, Wednesday, 05'th Feb 2025
NEW YORK , Feb. 5, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and Decemb
